MX2012001278A - Anticuerpos de dominio simple anti-receptor tgf-beta tipo ii. - Google Patents
Anticuerpos de dominio simple anti-receptor tgf-beta tipo ii.Info
- Publication number
- MX2012001278A MX2012001278A MX2012001278A MX2012001278A MX2012001278A MX 2012001278 A MX2012001278 A MX 2012001278A MX 2012001278 A MX2012001278 A MX 2012001278A MX 2012001278 A MX2012001278 A MX 2012001278A MX 2012001278 A MX2012001278 A MX 2012001278A
- Authority
- MX
- Mexico
- Prior art keywords
- fibrosis
- tgfbetarii
- tgf
- skin
- suitably
- Prior art date
Links
- 108010003723 Single-Domain Antibodies Proteins 0.000 title 1
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 title 1
- 101710084188 TGF-beta receptor type-2 Proteins 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004761 fibrosis Effects 0.000 abstract 2
- 102000018358 immunoglobulin Human genes 0.000 abstract 2
- 206010008909 Chronic Hepatitis Diseases 0.000 abstract 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 208000002260 Keloid Diseases 0.000 abstract 1
- 206010023330 Keloid scar Diseases 0.000 abstract 1
- 206010023421 Kidney fibrosis Diseases 0.000 abstract 1
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 238000010494 dissociation reaction Methods 0.000 abstract 1
- 230000005593 dissociations Effects 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 210000001117 keloid Anatomy 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 201000009925 nephrosclerosis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22933409P | 2009-07-29 | 2009-07-29 | |
| PCT/EP2010/060867 WO2011012609A2 (en) | 2009-07-29 | 2010-07-27 | Ligands that bind tgf-beta receptor rii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012001278A true MX2012001278A (es) | 2012-03-16 |
Family
ID=43067099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012001278A MX2012001278A (es) | 2009-07-29 | 2010-07-27 | Anticuerpos de dominio simple anti-receptor tgf-beta tipo ii. |
Country Status (15)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103443126B (zh) * | 2011-01-06 | 2016-11-23 | 葛兰素集团有限公司 | 结合TGFβ受体II的配体 |
| KR20180131557A (ko) * | 2016-04-05 | 2018-12-10 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 면역요법에서의 tgf베타의 억제 |
| GB201608052D0 (en) * | 2016-05-09 | 2016-06-22 | Univ Oslo Hf | T-cell receptors which recognise frameshift mutants of TGF-beta RII |
| JP2020501510A (ja) * | 2016-09-20 | 2020-01-23 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 目の表面で使用するためのアンカードメインを含む繋留タンパク質に基づく薬物 |
| US11713487B2 (en) | 2017-07-14 | 2023-08-01 | The Regents Of The University Of California | Methods of predicting transplant rejection risk |
| JP2021516966A (ja) | 2018-03-09 | 2021-07-15 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 組織への生物学的薬物の送達 |
| GB201807693D0 (en) * | 2018-05-11 | 2018-06-27 | Autolus Ltd | Cell |
| IL305181A (en) | 2021-02-15 | 2023-10-01 | Takeda Pharmaceuticals Co | Cell therapy compositions and methods for modulating tgf-b signaling |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| JP2001206899A (ja) * | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途 |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| CA2447851C (en) | 2001-06-28 | 2012-08-28 | Domantis Limited | Dual-specific ligand and its use |
| US20030028905A1 (en) * | 2001-07-31 | 2003-02-06 | Petra Knaus | Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms |
| WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| JP2004121001A (ja) * | 2002-08-07 | 2004-04-22 | Japan Tobacco Inc | ＴＧＦ−βＩＩ型受容体に対する高親和性モノクローナル抗体 |
| EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| AU2003290330A1 (en) | 2002-12-27 | 2004-07-22 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| AU2004239065B2 (en) | 2003-05-14 | 2008-05-15 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
| AU2004220325B2 (en) | 2003-06-30 | 2011-05-12 | Domantis Limited | Polypeptides |
| EP1675878A2 (en) | 2003-10-24 | 2006-07-05 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| EP1729795B1 (en) | 2004-02-09 | 2016-02-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1737962B1 (en) | 2004-03-24 | 2010-09-01 | Domantis Limited | Gas1 universal leader |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| CA2636854A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Ligands that bind il-4 and/or il-13 |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
-
2010
- 2010-07-27 EA EA201290028A patent/EA026097B1/ru not_active IP Right Cessation
- 2010-07-27 MX MX2012001278A patent/MX2012001278A/es not_active Application Discontinuation
- 2010-07-27 CA CA2768981A patent/CA2768981A1/en not_active Abandoned
- 2010-07-27 US US13/387,376 patent/US9109031B2/en not_active Expired - Fee Related
- 2010-07-27 WO PCT/EP2010/060867 patent/WO2011012609A2/en not_active Ceased
- 2010-07-27 BR BR112012001977A patent/BR112012001977A2/pt not_active Application Discontinuation
- 2010-07-27 CN CN2010800450323A patent/CN102574922A/zh active Pending
- 2010-07-27 EP EP10735014A patent/EP2459593A2/en not_active Withdrawn
- 2010-07-27 JP JP2012522147A patent/JP2013500030A/ja active Pending
- 2010-07-27 IN IN412DEN2012 patent/IN2012DN00412A/en unknown
- 2010-07-27 SG SG2012006029A patent/SG178135A1/en unknown
- 2010-07-27 AU AU2010277629A patent/AU2010277629B2/en not_active Ceased
- 2010-07-27 KR KR1020127005555A patent/KR20120063475A/ko not_active Ceased
-
2012
- 2012-01-10 IL IL217458A patent/IL217458A0/en unknown
- 2012-01-17 ZA ZA2012/00372A patent/ZA201200372B/en unknown
-
2015
- 2015-10-09 JP JP2015201067A patent/JP2016053039A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010277629A1 (en) | 2012-02-16 |
| US20120129778A1 (en) | 2012-05-24 |
| CN102574922A (zh) | 2012-07-11 |
| IL217458A0 (en) | 2012-02-29 |
| JP2013500030A (ja) | 2013-01-07 |
| KR20120063475A (ko) | 2012-06-15 |
| WO2011012609A3 (en) | 2011-09-15 |
| ZA201200372B (en) | 2013-06-26 |
| CA2768981A1 (en) | 2011-02-03 |
| EA026097B1 (ru) | 2017-03-31 |
| JP2016053039A (ja) | 2016-04-14 |
| EP2459593A2 (en) | 2012-06-06 |
| IN2012DN00412A (cg-RX-API-DMAC7.html) | 2015-05-22 |
| BR112012001977A2 (pt) | 2017-01-31 |
| EA201290028A1 (ru) | 2012-08-30 |
| AU2010277629B2 (en) | 2016-05-19 |
| WO2011012609A2 (en) | 2011-02-03 |
| SG178135A1 (en) | 2012-03-29 |
| US9109031B2 (en) | 2015-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012001278A (es) | Anticuerpos de dominio simple anti-receptor tgf-beta tipo ii. | |
| JP7007333B2 (ja) | 抗炎症活性を有するペプチド、及びそれを含む組成物 | |
| WO2013184960A3 (en) | Chimeric fibroblast growth factor 23 proteins and methods of use | |
| PH12013501397A1 (en) | Ligands that bind tgf-beta receptor ii | |
| JP2021011502A (ja) | 抗炎症活性を有するペプチド、及びそれを含む組成物 | |
| Hovanessian | Midkine, a cytokine that inhibits HIV infection by binding to the cell surface expressed nucleolin | |
| DK1765860T3 (da) | Ny-ESO-T.cellereceptor med höj affinitet | |
| PE20191551A1 (es) | Polipeptidos de union al receptor de transferrina disenados | |
| MX336391B (es) | Metodos y composiciones que usan polipeptidos de fusion de fgf23. | |
| JP2017000143A5 (cg-RX-API-DMAC7.html) | ||
| HRP20151227T1 (hr) | Sastavi i postupci uporabe za terapeutska protutijela | |
| PE20090322A1 (es) | Fraccion de anticuerpo y anticuerpo antagonista del factor de crecimiento endotelial vascular | |
| SI3134430T1 (en) | ENVIRONMENTAL PROTEINS TRAIL RECEPTORS AGENTS | |
| WO2019147944A8 (en) | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents | |
| US11447559B2 (en) | Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same | |
| MX350273B (es) | Proteinas de fusion para el tratamiento de trastornos metabolicos. | |
| MX2010002053A (es) | Composiciones de proteinas de fusion de notch humanizadas y metodos de tratamiento. | |
| PE20091713A1 (es) | Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos | |
| EP3345925A3 (en) | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods | |
| MX2022005850A (es) | Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo. | |
| EP2403871A4 (en) | FOR ABUSED PRION PROTEIN SPECIFIC ANTIBODIES AND EPITOPES | |
| CN101553501A (zh) | Il-21变种 | |
| NZ599114A (en) | Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists | |
| NO20073239L (no) | TNF-antagonister | |
| EP3955956A1 (en) | Therapeutic crosslinking of cytokine receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |